You can buy or sell KIN and other stocks, options, ETFs, and crypto commission-free!
Kindred Biosciences, Inc. Common Stock, also called Kindred Biosciences, is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. Read More The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Kindred Bio: Call Me Inappetent
Kindred Bio (KIN) develops drugs for animals. The original idea was to study available generic drugs for humans that were already used for animals without proper trials or FDA approval, create a smart formulation which would be hard to copy (e.g., a transdermal patch) and a brand, and finally, sell these drugs through veterinarians. Since veterinarians not only treat pets but also sell the drugs they need (which our physicians are prohibited to do), veterinarians like new branded drugs a lot, as these allo...
The Motley FoolMar 6
Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript
Kindred Biosciences Inc (NASDAQ:KIN) Q4 2018 Earnings Conference Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Welcome to the Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast for Kindred Biosciences. (Operator Instructions) Please note that the remarks today will include forward-looking statements and that actual results could differ materially from those projected or implied in our forward-looking s...
Seeking AlphaMar 6
Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q4 2018 Results - Earnings Call Transcript
Kindred Biosciences, Inc. (NASDAQ:KIN) Q4 2018 Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Richard Chin - Chief Executive Officer Denise Bevers - President & Chief Operating Officer Wendy Wee - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Ben Haynor - Alliance Global Partners Andrew DeSilva - B. Riley FBR Swayampakula Ramakanth - H.C. Wainwright Brooks O'Neil - Lake Street Capital Markets David Westenberg - Guggenheim Securitie...
-$0.43 per share
-$0.46 per share